CellWise is the turn-key translation layer between a single-cell run and a report a clinician can act on. License it, co-brand it, or white-label it into the menu of services you already sell.
CellWise sits between raw single-cell data and the clinician, so both sides of the market can sell it as their own.
You operate the single-cell sequencing instruments. CellWise turns the HDF5 and Seurat objects into structured, clinician-ready reports, so you can layer software margin on top of the assays already moving through your lab.
You have the patient relationship and a menu of services. CellWise gives you single-cell decision support to sell inside it, co-branded or fully white-labeled, without standing up a computational-biology team of your own.
The parts that are hard to build in-house: the translation, the quality control, and the clinical engines on top.
Raw single-cell files in, structured clinician-ready reports out, through the Ellmer API. Your team ships a clinical product without hiring computational biologists to interpret HDF5 or Seurat objects.
Strict filters remove apoptotic cells, and MAD-based normalization against a population baseline eliminates batch effects while keeping the rare functional anomalies that mean/standard-deviation methods erase.
License the Peptide Atlas, Cellular Aging Profile, and Clinical Surveillance as individual line items, or the full seven-module workspace. Priced so the software margin sits above the cost of the assay.
Four ways to bring CellWise to market, from fastest-to-launch to fully your own.
Your mark alongside CellWise. The fastest path to market, with shared credibility on every report your patients and clinicians see.
Fully your brand. CellWise powers the science silently while you own the interface, the naming, and the report templates.
Pipe results straight into your existing LIS or patient portal through the Ellmer API, and add single-cell to the menu you already run.
License the engines as catalog line items and sell them inside your current test menu, priced and branded as your own service.
The clinical home base. Use-case assessments, immuno-metabolic phenotyping, the therapeutic target map, stress profiling, and more, all in one report.
The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.
A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.
Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.
Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.
Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.
Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.
The technical and commercial reasons a lab or health-services company can put its name on the output.
Transforming HDF5 and Seurat objects into something a referring physician can read used to require a computational-biology team we didn't have. This is the translation layer that lets us monetize the sequencing we already run.
The MAD normalization against a population baseline is what makes the output reproducible enough for us to put our own name on it across sample runs.
White-labeling a validated single-cell service into our existing menu is a new revenue line we could never have built the science for on our own.